Benjamin Ferland

Brigham and Women's Hospital

Papers

1

Total Citations

7

H-Index

1

About

Benjamin Ferland is a pioneering translational researcher in thoracic oncology, whose work centers on precision medicine for non-small cell lung cancer (NSCLC). His most significant contribution is the first-in-human proof-of-concept study demonstrating the safety and feasibility of implanting multidrug-eluting microdevices directly into lung tumors during surgery. This innovative approach allows for in situ chemotherapeutic sensitivity testing, enabling real-time assessment of drug efficacy within a patient’s own tumor microenvironment—a breakthrough that could revolutionize personalized adjuvant therapy. Ferland’s landmark 2022 paper, cited 7 times, provides the foundational evidence for this technology, addressing the critical challenge of predicting optimal treatment regimens to improve postsurgical outcomes. His work bridges surgical oncology and drug development, offering a novel platform to bypass traditional trial-and-error prescribing. By validating the implantation and retrieval of these microdevices in NSCLC patients, Ferland has opened a new frontier in functional precision oncology, with potential to spare patients from ineffective therapies and accelerate the identification of effective drug combinations.

Research Focus

Key Achievements

1
H-Index
1
Papers
7
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer
7 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Brigham and Women's Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago